Trial reportNeuro-oncology2010
Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease.
Trial report in Neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Stereotactic radiosurgery in the management of central nervous system hemangioblastomas: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis.Journal of neuro-oncology · 2018Pooled it
- Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease.Journal of neurosurgery · 2014Trial
- When is belzutifan the right option for von Hippel-Lindau disease-associated hemangioblastomas?-a critical review of LITESPARK-004 results.Translational cancer research · 2025Article
- Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance.Journal of Korean Neurosurgical Society · 2025Article
- Spinal cord hemangioblastomas in von Hippel-Lindau disease.Neuro-oncology advances · 2024Review
- The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.Cancers · 2024Review
- Radiosurgically Treated Recurrent Cerebellar Hemangioblastoma: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Time course of tumorigenesis of a newly developed sporadic hemangioblastoma in an elderly patient: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Supratentorial hemangioblastoma: correlation between phenotype, gender and vascular territory affected.Neurosurgical review · 2023Article
- Neurological applications of belzutifan in von Hippel-Lindau disease.Neuro-oncology · 2023Article
- Hemangioblastomas and Other Vascular Origating Tumors of Brain or Spinal Cord.Advances in experimental medicine and biology · 2023Review
- VHL: Trends and Insight into a Multi-Modality, Interdisciplinary Approach for Management of Central Nervous System Hemangioblastoma.Acta neurochirurgica. Supplement · 2023Review
- Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: a multicenter retrospective case series.Journal of neuro-oncology · 2023Article
- Neuropathologic features of central nervous system hemangioblastoma.Journal of pathology and translational medicine · 2022Review
- Clinical characteristics, surgical management, and prognostic factors for supratentorial hemangioblastoma: A retrospective study.Frontiers in surgery · 2022Article
- Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report.Frontiers in oncology · 2022Article
- Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Article
- Clinical diagnosis, treatment and screening of the VHL gene in three von Hippel-Lindau disease pedigrees.Experimental and therapeutic medicine · 2020Article
- Von Hippel-Lindau Disease: Current Challenges and Future Prospects.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
To determine the effectiveness of stereotactic radiosurgery (SRS) treatment to central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL), we analyzed long-term results in VHL patients treated with SRS. Patients were enrolled in a prospective VHL natural history study, undergoing SRS treatment of CNS hemangioblastomas. Treatment regimens, serial clinical evaluations, and longitudinal imaging data were analyzed. Twenty VHL patients (10 males and 10 females) underwent SRS treatment of 44 CNS hemangioblastomas (39 cerebellar and 5 brainstem). Mean (+/-SD) age at treatment was 37.5 +/- 12.0 years (range: 13-67). Mean follow-up was 8.5 +/- 3.2 years (range: 3.0-17.6 years). All patients were alive at last follow-up. Mean treated tumor volume was 0.5 +/- 0.7 cm(3) (range: 0.01-3.6 cm(3)). Mean prescription dose was 18.9 Gy (range: 12-24 Gy) at the tumor margin. Local control rate at 2, 5, 10, and 15 years after SRS treatment was 91%, 83%, 61%, and 51%, respectively. Univariate analysis did not identify variables associated (P > .05) with worse tumor control at last follow-up. Thirty-three percent of SRS-treated small (<1.0 cm diameter), asymptomatic tumors progressed over a long-term follow-up. There were no long-term adverse radiation effects. Although SRS treatment of hemangioblastomas in VHL has a low risk for adverse radiation effects, it is associated with diminishing control over a long-term follow-up. These results indicate that SRS should not be used to prophylactically treat asymptomatic tumors and should be reserved for the treatment of tumors that are not surgically resectable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.